Skip to main content
. 2020 Jul 27;151:314–321. doi: 10.1016/j.radonc.2020.04.019

In scenario 1, risk mitigation:

Do not alter standard HNSCC radical radiation dose fractionation. Agreement
Continue to use concomitant chemotherapy. Strong agreement
Continue to use the standard concomitant chemotherapy schedule. Agreement
Do not use induction chemotherapy for locoregionally advanced larynx SCC. Majority, near-agreement